An international group of researchers led by Children’s Hospital of Philadelphia, Winship Cancer Institute of Emory University, and the New Approaches to Neuroblastoma Therapy Consortium showed that the targeted therapy Lorbrena (lorlatinib) is safe and effective in treating high-risk neuroblastoma.
Results from a clinical trial conducted by researchers at NIH show that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis. Lymphomatoid granulomatosis is a rare precancerous condition triggered by Epstein-Barr virus infection. Left untreated, the disease can progress to a high-grade form, which has a poorer prognosis and can quickly turn into an aggressive and fatal B-cell lymphoma.
Researchers from MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer.
Researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute have demonstrated for the first time that microRNA expression leads to a diversity of cancer stem cells within a colorectal cancer tumor. This diversity of cancer cells may explain why advanced colorectal cancer is difficult to treat.
FDA approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
The National Cancer Institute approved the following clinical research studies last month.
In a phase III NRG‑GY018 trial investigating Keytruda (pembrolizumab) in combination with standard of care chemotherapy (carboplatin and paclitaxel) for the first-line treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient or mismatch repair deficient, the Keytruda regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients, regardless of mismatch repair status.
In the phase III RUBY clinical trial, the Jemperli regimen showed a statistically significant and clinically meaningful improvement in progression free survival in the mismatch repair deficient/microsatellite instability-high population and in the overall population.
Researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators have shown that immature natural killer cells are present in patients with triple-negative breast cancer and likely promote, instead of inhibit, disease progression in this cancer type.
An interim analysis of NATALEE, a phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence demonstrated positive topline results.
